421 related articles for article (PubMed ID: 8876907)
1. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
2. Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
Trinkaus ME; Hicks RJ; Young RJ; Peters LJ; Solomon B; Bressel M; Corry J; Fisher R; Binns D; McArthur GA; Rischin D
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):89-97. PubMed ID: 24529061
[TBL] [Abstract][Full Text] [Related]
3. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.
Lee DJ; Trotti A; Spencer S; Rostock R; Fisher C; von Roemeling R; Harvey E; Groves E
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):811-5. PubMed ID: 9845102
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
5. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
6. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.
Overgaard J
Radiother Oncol; 2011 Jul; 100(1):22-32. PubMed ID: 21511351
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
Lee DJ; Pajak TF; Stetz J; Order SE; Weissberg JB; Fischer JJ
Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
[TBL] [Abstract][Full Text] [Related]
9. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
[TBL] [Abstract][Full Text] [Related]
10. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
12. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
Fazekas J; Pajak TF; Wasserman T; Marcial V; Davis L; Kramer S; Rotman M; Stetz J
Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
[TBL] [Abstract][Full Text] [Related]
13. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
Sealy R; Cridland S; Barry L; Norris R
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1343-6. PubMed ID: 3531113
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
Rischin D; Hicks RJ; Fisher R; Binns D; Corry J; Porceddu S; Peters LJ;
J Clin Oncol; 2006 May; 24(13):2098-104. PubMed ID: 16648512
[TBL] [Abstract][Full Text] [Related]
15. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
16. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer.
Fu KK; Cooper JS; Marcial VA; Laramore GE; Pajak TF; Jacobs J; Al-Sarraf M; Forastiere AA; Cox JD
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):425-38. PubMed ID: 8655364
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
19. Developments in radiotherapy and adjuvant chemotherapy for head and neck cancer.
Glaholm J; Watkinson JC
Clin Otolaryngol Allied Sci; 2003 Feb; 28(1):1-4. PubMed ID: 12580871
[No Abstract] [Full Text] [Related]
20. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
